Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Collagenase Type I is a proteolytic enzyme that breaks down the peptide bonds in collagen, the main structural protein of connective tissue. Collagenase has been explored as a potential treatment option to break down herniated disc material, thereby reducing pressure on nearby nerves. Collagenase may aid in the breakdown and reorganization of excessive scar tissue, potentially improving tissue function and appearance. Collagenase has the potential to treat disc herniation, keloid, cellulite, lipoma, as well as Peroni's disease and palm fibromatosis.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
50 mg | In stock | $ 39.00 | |
100 mg | In stock | $ 55.00 |
Description | Collagenase Type I is a proteolytic enzyme that breaks down the peptide bonds in collagen, the main structural protein of connective tissue. Collagenase has been explored as a potential treatment option to break down herniated disc material, thereby reducing pressure on nearby nerves. Collagenase may aid in the breakdown and reorganization of excessive scar tissue, potentially improving tissue function and appearance. Collagenase has the potential to treat disc herniation, keloid, cellulite, lipoma, as well as Peroni's disease and palm fibromatosis. |
In vitro | The objective of this study was to determine whether a peptide of type II collagen which can induce collagenase activity can also induce chondrocyte terminal differentiation (hypertrophy) in articulate cartilage. Results show that the induction of collagenase activity by a cryptic peptide sequence of type II collagen is accompanied by chondrocyte hypertrophy and associated with cellular and matrix changes. This induction occurs in the mid and superficial zones of previously healthy articular cartilage. This response of the chondrocyte to a cryptic sequence of denatured type II collagen may play a role in naturally occurring hypertrophy in endochondral ossification and in the development of cartilage pathology in osteoarthritis.[1] |
In vivo | Ten New Zealand white rabbits were used as the experimental group and control group. After epithelial debridement, a collagenase type II solution (200 μL of 5 mg/mL) was applied in the experimental group at room temperature (24 °C) for 30 min, and a 200 μL solution without collagenase was applied in the control group. No obvious inflammatory reaction was observed in all eyes after the procedure. The differences in elastic modulus between the experimental and control group were statistically significant at 10% and 15% deformities. Collagenase type II treatment results in mimic KC with increased corneal keratometry and corneal thinning and a lower elastic modulus. An animal model for corneal ectasia can be generated by treatment with collagenase type II.[2] |
Synonyms | Collagenase I, Collagenase Type I (From microorganisms) |
Molecular Weight | N/A |
CAS No. | 9001-12-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Collagenase Type I 9001-12-1 Others Collagenase I Collagenase Type I (From microorganisms) inhibitor inhibit